Modern Treatments
Modern GLP-1 Treatment Options
The modern GLP-1 treatment landscape spans brand-name and compounded options, telehealth prescribers, and a rapidly shifting insurance environment. These guides help you navigate specific medications, understand the differences between branded drugs, evaluate access routes, and the practical realities of getting and staying on treatment.
Start here
Featured guides
Ozempic Savings Card: How to Pay $25/Month
Novo Nordisk's Ozempic savings card can reduce your monthly cost to $25 — but eligibility rules catch a lot of people off guard. Here is exactly how it works and who qualifies.
Semaglutide vs. Tirzepatide: How the Two Big Drugs Compare
They're the two most-discussed GLP-1 medications, but they aren't the same drug. Here's a plain-language comparison of mechanism, results, and trade-offs.
All guides
34 more in Modern Treatments
Tirzepatide Brand Names: Mounjaro vs. Zepbound — Which to Ask For
Mounjaro and Zepbound are both tirzepatide at the same doses. The brand you ask for determines your coverage — and getting this wrong can mean paying thousands more per year for an identical drug.
Can You Get a GLP-1 Without an In-Person Doctor Visit?
Most people starting GLP-1 medications today never set foot in a doctor's office to get their prescription. Here's how telehealth works, what the process actually involves, and what to watch out for.
GLP-1 Injection Day: Small Habits That Make It Easier
The weekly injection is simple once it's routine. A short, practical guide to timing, sites, storage, and the little things that smooth it out.
How to Choose a GLP-1 Telehealth Provider Without Getting Burned
The telehealth market is crowded, and not all providers are equal. A practical checklist for separating real clinical care from a slick checkout page.
What GLP-1 Medications Actually Cost — and How to Pay Less
List prices are eye-watering, but very few people pay them. Here's how insurance, savings cards, and compounding change the real number.
Semaglutide and Heart Disease: The SELECT Trial
Semaglutide and heart disease: the SELECT trial showed Wegovy cut major cardiovascular events about 20% in adults with heart disease and obesity but no diabetes, a first for a weight-loss drug.
GLP-1 for Teens: Wegovy for Adolescents
GLP-1 for teens is now an FDA-approved option: Wegovy (semaglutide) and Saxenda (liraglutide) are cleared for adolescents 12 and older with obesity. Here is the trial evidence, who qualifies, the safety profile, and the honest debate around medicating young people.
GLP-1 and Kidney Disease: The FLOW Trial
How GLP-1 and kidney disease intersect: the FLOW trial showed semaglutide cut major kidney events by about 24% in people with type 2 diabetes and chronic kidney disease.
GLP-1 and Fatty Liver (MASH): What the Evidence Shows
GLP-1 and fatty liver: how semaglutide, tirzepatide, and the GLP-1 drug class affect MASLD and MASH (formerly NAFLD/NASH), what the trial evidence shows, the regulatory status as of 2026, and why treating obesity treats the liver.
Showing 9 of 34 guides
Explore more
Other topic areas
01
The Science Behind GLP-1
Evidence-based explanations of GLP-1, semaglutide, appetite regulation, and modern obesity science.
Browse guides →02
How Your Metabolism Actually Works
Articles about metabolism, insulin resistance, energy balance, metabolic adaptation, and weight regulation.
Browse guides →03
The Biology of Appetite and Hunger
Science-backed insights into hunger, satiety, cravings, and appetite hormones.
Browse guides →04
What the Weight Loss Research Actually Shows
Breakdowns of modern obesity research, clinical studies, and emerging metabolic science.
Browse guides →